| Bioactivity | RO0711401 is a selective and orally active positive allosteric modulator of mGlu1 receptor with an EC50 of 56 nM[1][2]. | ||||||||||||
| In Vivo | RO0711401 (10 mg/kg; s.c.; once) causes a long-lasting improvement in motor performance, which is maintained to the same extent at least for 6 days[1].Systemic injection of RO0711401 is shown to reduce the frequency of spike-and-wave discharges in a rat model of absence epilepsy, and to improve motor signs in autoimmune encephalomyelitis (EAE) mice[1]. Animal Model: | ||||||||||||
| Name | RO0711401 | ||||||||||||
| CAS | 714971-87-6 | ||||||||||||
| Formula | C18H11F3N2O3 | ||||||||||||
| Molar Mass | 360.29 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Serena Notartomaso, et al. Pharmacological enhancement of mGlu1 metabotropic glutamate receptors causes a prolonged symptomatic benefit in a mouse model of spinocerebellar ataxia type 1. Mol Brain. 2013 Nov 19;6:48. [2]. Eric Vieira, et al. Fluorinated 9H-xanthene-9-carboxylic acid oxazol-2-yl-amides as potent, orally available mGlu1 receptor enhancers. Bioorg Med Chem Lett. 2009 Mar 15;19(6):1666-9. |